FRANCISCO JAVIER
SALMERÓN ESCOBAR
Investigador en el periodo 2002-2020
Conrado M.
Fernández Rodriguez
Publicaciones en las que colabora con Conrado M. Fernández Rodriguez (17)
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH
Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676
-
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort
Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64
2018
-
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349
-
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))
Gastroenterologia y Hepatologia
-
Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry
Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502
-
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270
2017
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2015
-
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174
2014
-
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study
Gastroenterologia y Hepatologia, Vol. 37, Núm. 1, pp. 1-8
2009
-
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
Hepatology, Vol. 50, Núm. 6, pp. 1702-1708
2008
-
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C
Journal of Hepatology, Vol. 48, Núm. 5, pp. 721-727
2005
-
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
Gastroenterology, Vol. 128, Núm. 3, pp. 636-641